Review
2021. The year in review. Structural heart interventions

https://doi.org/10.1016/j.ijcard.2022.04.023Get rights and content

Highlights

  • •

    Sustained TAVR benefits in low and intermediate-risk.

  • •

    TAVR effective for bicuspid aortic AV and cancer.

  • •

    New TEER guidelines.

  • •

    Sustained outcomes with MitraClip, PASCAL, TENDYNE.

Abstract

Since the beginning of 2020, the corona virus (COVID-19) pandemic redefined in many ways the practice of cardiology, research and cardiology conferences. Virtual conferences replaced most major in-person venues. The number of “elective” structural heart interventions declined and clinical research endured major setbacks in regards to academic and industry-sponsored clinical trials. In this review, we attempt to provide a broad overview of the field for general and interventional cardiologists with a specific interest in structural heart interventions.

Keywords

Structural
TAVR
MitraClip
LAAO
PFO
2021

Abbreviations

ACC
American College of Cardiology
SCAI
Society of Cardiovascular Angiography and Interventions
TCT
Transcatheter Cardiovascular Therapeutics
ESC
European Society of Cardiology
CRT
Cardiovascular Research Technologies (CRT)
AHA
American Heart Association
EACTS
European Association for Cardio-Thoracic Surgery
AS
aortic stenosis
TAVR
transcatheter aortic valve replacement
SAVR
Surgical aortic valve replacement
RCT
randomized-controlled trial
FDA
US Food and Drug Administration
IDE
Investigational Device Exemption
AMI
acute myocardial infarction
HF
heart failure
CAD
coronary artery disease
PCI
percutaneous coronary intervention
CT
computed tomography
VKA
vitamin K antagonists
KCCQ-OS
Kansas City Cardiomyopathy Questionnaire Overall Summary Score
AKI
acute kidney injury
CKD
Chronic kidney disease

Cited by (0)

View Abstract
© 2022 Published by Elsevier B.V.